Zeven (dalbavancin) / RaQualia, AbbVie 
Welcome,         Profile    Billing    Logout  
 20 Diseases   6 Trials   6 Trials   1040 News 


«12...45678910111213141516»
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    [VIRTUAL] Case 2 - DALBAVANCIN USE IN A NEONATE WITH OSTEOMYELITIS (Hall 01) -  May 4, 2021 - Abstract #ESPID2021ESPID_732;    
    Learning Points/ This is the first reported case of Dalbavancin safely given to an infant with osteomyelitis. This approach may reduce the length of hospital stay and allow the earlier removal of the central venous catheters.
  • ||||||||||  Journal:  Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. (Pubmed Central) -  May 1, 2021   
    This approach may reduce the length of hospital stay and allow the earlier removal of the central venous catheters. Considering the similar efficacy that arose from direct comparisons in phase-3 RCTs, in order to adopt the best approach for treating ABSSSI on patient-tailored basis, the different safety profiles and formulations of the different available agents should be balanced by taking into account the specific features of each treated patient in terms of baseline comorbidities, related risk of toxicity, need for hospitalization, possibility of early discharge, and expected adherence to outpatient oral therapy.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Enrollment open, Head-to-Head:  DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (clinicaltrials.gov) -  Apr 29, 2021   
    P2b,  N=200, Recruiting, 
    Although some of these approved antibiotics are promising, they should not be used as first- or second-line therapy, awaiting more clinical data. Not yet recruiting --> Recruiting
  • ||||||||||  Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Mammary Dysbiosis and Nipple Blebs Treated With Intravenous Daptomycin and Dalbavancin. (Pubmed Central) -  Apr 2, 2021   
    Future studies are needed to evaluate the feasibility and effectiveness of these new alternatives on the PWID population. We report that in patients with a multi-drug-resistant, methicillin-resistant Staphylococcus aureus-positive human milk culture and a clinical presentation of mammary dysbiosis and nipple blebs, intravenous daptomycin and dalbavancin may be an effective treatment.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Review, Journal:  Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization. (Pubmed Central) -  Apr 2, 2021   
    One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, PK/PD data, Journal:  Evaluation of intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients. (Pubmed Central) -  Mar 23, 2021   
    Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events. Dalbavancin 1500 mg intravenously can be utilized without dose adjustment in peritoneal dialysis patients and will likely achieve necessary peritoneal fluid concentrations to treat peritonitis caused by typical gram-positive pathogens.
  • ||||||||||  Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Review, Journal:  Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. (Pubmed Central) -  Mar 16, 2021   
    Current evidence also suggests that these agents may be cost-effective from patient, payer, and hospital perspectives. Barriers to broader use of laLGPs include, among others, a relative lack of prospective data regarding efficacy in serious infections, a narrow United States Food and Drug Administration-approved indication restricted to only acute bacterial skin and skin structure infections, and lack of reimbursement infrastructure for inpatient settings.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Preclinical, Journal:  Dalbavancin: novel candidate for COVID-19 treatment. (Pubmed Central) -  Mar 16, 2021   
    Barriers to broader use of laLGPs include, among others, a relative lack of prospective data regarding efficacy in serious infections, a narrow United States Food and Drug Administration-approved indication restricted to only acute bacterial skin and skin structure infections, and lack of reimbursement infrastructure for inpatient settings. No abstract available
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). (Pubmed Central) -  Mar 12, 2021   
    Since the emergence of MRSA, the management of ABSSSI has become more challenging. Novel therapies alternative to teicoplanin and vancomycin, intravenous agents commonly used against MRSA and employed in hospitalized patients, and to other antibiotics which are used as standard of care for MRSA infection, with a higher efficacy and safer profile are worth evaluating.Areas covered: This review presents and discusses current evidence on the use of dalbavancin in the treatment of ABSSSI.Expert opinion: Dalbavancin represents a promising therapeutic choice in patients with ABSSSI, thanks to its favorable pharmacokinetic profile, valuable antimicrobial spectrum, and good safety profile.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Trial primary completion date, Gram positive:  Dalbavancin Outpatient Pilot (clinicaltrials.gov) -  Mar 2, 2021   
    P4,  N=24, Not yet recruiting, 
    Clinical assessment at that time may allow for considering whether or not an additional dose should be administered for prolonging effective treatment. Trial primary completion date: Jun 2021 --> Nov 2021
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Preclinical, Journal:  Dalbavancin and wound healing: new evidences/insights in a mouse model of skin infection. (Pubmed Central) -  Jan 29, 2021   
    The wounds treated with dalbavancin showed robust epidermal coverage with a reconstitution of the regular and keratinized epidermal lining and a well-organized granulation tissue with numerous blood vessels, although slightly less than in the uninfected group, while in vancomycin treated group the epithelium appeared in general still hypertrophic, the granulation tissue appears even less organized.We observed elevated EGFR and VEGF expression in both treated groups, although it was higher in dalbavancin treated mice. MMP-1 and MMP-9 were decreased in uninfected and in both treated tissue when compared with untreatd infected wounds.This study showed faster healing with dalbavancin treatment that might be associated with a higher EGFR and VEGF levels.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Dalbavancin combined with linezolid in prosthetic-hip infection (Pubmed Central) -  Jan 23, 2021   
    The authors present a case of a patient with shoulder phlegmon caused by MRSA who was successfully treated with this antibiotic. No abstract available
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Structural Basis for the Binding Mechanism of Human Serum Albumin Complexed with Cyclic Peptide Dalbavancin. (Pubmed Central) -  Jan 23, 2021   
    The flip of Leu251 promoted the formation of the binding pocket with an induced-fit mechanism; moreover, the movement of the loop region including Glu60 increased the number of noncovalent interactions with HSA. These findings may support the development of new cyclic peptides for clinical use, particularly the elucidation of their binding mechanism to HSA.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Experience in the use of dalbavancin in diabetic foot infection. (Pubmed Central) -  Jan 17, 2021   
    Patients with osteomyelitis due to gram-positive microorganisms who received as part of the multidisciplinary antibiotic treatment with dalbavancin, had a high rate of cure with adequate tolerance and few side effects. Dalbavancin offers a safe alternative in treating deep diabetic foot infection.